London · Delayed Price · Currency is GBP · Price in USD Centessa Pharmaceuticals Statistics
Total Valuation
| Market Cap | n/a |
| Enterprise Value | n/a |
Important Dates
The last earnings date was Tuesday, August 4, 2026.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +14.73% |
| Shares Change (QoQ) | +8.15% |
| Owned by Insiders (%) | 0.64% |
| Owned by Institutions (%) | 58.21% |
| Float | 92.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.53, with a Debt / Equity ratio of 0.24.
| Current Ratio | 9.53 |
| Quick Ratio | 9.27 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.57 |
| Interest Coverage | -22.69 |
Financial Efficiency
Return on equity (ROE) is -57.38% and return on invested capital (ROIC) is -28.90%.
| Return on Equity (ROE) | -57.38% |
| Return on Assets (ROA) | -27.43% |
| Return on Invested Capital (ROIC) | -28.90% |
| Return on Capital Employed (ROCE) | -42.41% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.47M |
| Employee Count | 129 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, LON:0ACX has paid 963,292 in taxes.
| Income Tax | 963,292 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +228.81% in the last 52 weeks. The beta is 1.12, so LON:0ACX's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | +228.81% |
| 50-Day Moving Average | 39.66 |
| 200-Day Moving Average | 28.26 |
| Relative Strength Index (RSI) | 77.17 |
| Average Volume (20 Days) | 2,523 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.87 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -194.39M |
| Pretax Income | -188.85M |
| Net Income | -189.81M |
| EBITDA | -194.13M |
| EBIT | -194.39M |
| Earnings Per Share (EPS) | -1.35 |
Balance Sheet
The company has 209.46 million in cash and 89.78 million in debt, with a net cash position of 119.68 million.
| Cash & Cash Equivalents | 209.46M |
| Total Debt | 89.78M |
| Net Cash | 119.68M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 369.07M |
| Book Value Per Share | 2.39 |
| Working Capital | 236.36M |
Cash Flow
In the last 12 months, operating cash flow was -158.12 million and capital expenditures -280,960, giving a free cash flow of -158.40 million.
| Operating Cash Flow | -158.12M |
| Capital Expenditures | -280,960 |
| Depreciation & Amortization | 259,363 |
| Net Borrowing | n/a |
| Free Cash Flow | -158.40M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0ACX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.73% |
| Shareholder Yield | -14.73% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0ACX has an Altman Z-Score of 7.55 and a Piotroski F-Score of 1.
| Altman Z-Score | 7.55 |
| Piotroski F-Score | 1 |